Scribe Therapeutics, a biotech company focusing on epigenetic silencing, recently went public, raising $150 million and seeing a 43% increase in its stock price. It is currently leading the way with its asset STX-1150, which is designed to lower ‘bad’ LDL cholesterol without making permanent DNA changes, and has just entered Phase 1 trials in Australia. Analysts believe Scribe’s model of offering a lower IPO valuation may lead to positive market performance, especially with anticipated interim trial results in early 2024. With backing from prominent pharmaceutical companies and a strong cash runway, Scribe aims to validate its innovative approach in the competitive biotech landscape.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/business/scribes-early-stage-ipo-standout-defies-biotechs-derisking-trend
